Marek Zatloukal

This inventor holds 18 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 20 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Univerzita Palackeho V Olomouci, Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky, Ustav Experimentalni Botaniky Av Cr, V.v.i.. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marek Zatloukal. Retrieved from https://idiyas.com/inventor/marek-zatloukal

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 5)

% Patents Active = 44.4

CIPO Patents = 4

EPO Patents = 20 (Patent Applications = 18)

Average Co-Inventor Count = 7.4

ph-index = 2

Forward Citations = 24(Granted Patents)

Company Filing History:

10 out of 36

Univerzita Palackeho V Olomouci

patents

3 out of 3

Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky

patents

3 out of 5

Ustav Experimentalni Botaniky Av Cr, V.v.i.

Fakultni Nemocnice Olomouc

patent

7. 1 out of 25

Freie Universitat Berlin

patents

8. 1 out of 1

Institute of Experimental Botany, Academy of Sciences of the Czech Republic

patent

9. 1 out of 1

Institute of Experimental Botany, Academy of Sciences of the Czeck Republic

patent

10. 1 out of 1

Univerzita Palackego V Olomouci

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

Purine Derivatives

Cytokinins

Neuroprotection

Plant Stress Inhibition

Medicinal Applications

Cosmetic Compositions

Pharmaceutical Preparations

Skin Disorders

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12570657 - Mesylate salts of heterocyclic cytokinins, compositions containing these derivatives and use thereof (2026-03-10),

2. 12378247 - Mesylate salt of para-topolin, compositions containing said salt and use thereof (2025-08-05),

3. 12319694 - Heterocyclic nitrogen-containing purine derivatives, pharmaceutical preparations containing these derivatives and their use in neuroprotection (2025-06-03),

4. 11643413 - 9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders (2023-05-09),

5. 10662194 - Substituted 6-anilino-9-heterocyclylpurine derivatives for inhibition of plant stress (2020-05-26),

6. 10550144 - 6-aryl-9-glycosylpurines and use thereof (2020-02-04),

7. 10100077 - 6-aryl-9-glycosylpurines and use thereof (2018-10-16),

8. 10093675 - 6,8-disubstituted-9-(heterocyclyl)purines, compositions containing these derivatives and their use in cosmetic and medicinal applications (2018-10-09),

9. 9993002 - 1,2,3-thiadiazol-5yl-urea derivatives, use thereof for regulating plant senescence and preparations containing these derivatives (2018-06-12),

10. 9073961 - [object Object] (2015-07-07),

11. 9023857 - Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds (2015-05-05),

12. 8575182 - 6, 9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions (2013-11-05),

13. 8552013 - [object Object] (2013-10-08),

14. 8492391 - Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containing these derivatives (2013-07-23),

15. 8222260 - Substituted 6-anilinopurine derivatives as inhibitors of cytokinin oxidase/dehydrogenase and preparations containing these derivatives (2012-07-17),

Title: **Marek Zatloukal: A Pioneer in Purine Derivatives**

Introduction

Marek Zatloukal, an innovative inventor based in Šumperk, Czech Republic, has made significant contributions to the field of pharmaceuticals and agriculture through his inventive spirit. With a remarkable portfolio of 15 patents, he continues to push the boundaries of science and technology.

Latest Patents

Among his notable recent inventions are two groundbreaking patents. The first patent is for "9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders". This invention pertains to N,N-disubstituted-9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives, utilized as drugs and cosmetics. The derivatives exhibit remarkable biological activities related to oxidative stress inhibition, including anti-aging, anti-inflammatory, and anti-neurodegenerative effects. The invention also encompasses cosmetic and pharmaceutical compositions containing these derivatives as active agents.

The second patent involves "Substituted 6-anilino-9-heterocyclylpurine derivatives for inhibition of plant stress". This innovation focuses on substituted 6-anilino-9-heterocyclylpurine derivatives, which are valuable for mitigating plant stress. The compounds feature a variety of substituents and a five- or six-membered heterocyclic ring containing one oxygen atom, making them essential in advancing agricultural practices.

Career Highlights

Marek Zatloukal has collaborated with esteemed institutions such as Palacký University Olomouc and the Institute of Experimental Botany of the Czech Academy of Sciences. His work in these organizations has allowed him to apply his inventive ideas in a collaborative environment, driving innovation in both pharmaceutical and agricultural sectors.

Collaborations

Throughout his career, Zatloukal has had the opportunity to work alongside talented individuals, including Karel Doležal and Miroslav Strnad. These collaborations have likely enriched his research and led to the successful development of his patents.

Conclusion

Marek Zatloukal stands out as a dedicated inventor whose contributions have substantial implications for healthcare and agriculture. Through his innovative patents and collaborative spirit, he continues to inspire future developments in these fields, showcasing the power of creativity in tackling complex challenges.

Profile summary based on public USPTO records.